BioVaxys Technology Corp.

BIOV

CA09076M1014

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:35:54 15/05/2024 BST			5-day change	1st Jan Change
0.07 ^CAD	-12.50%		-.--%	+40.00%

05-02	Biovaxys Technology Corp. Delays to File Its Interim Financial Statements for the Three Months Ended January 31, 2024	CI
04-30	BioVaxys Technology Corp. Appoints Christopher Cherry as Chief Financial Officer	CI

Biovaxys Technology Corp. Appoints Anthony Dutton as A Director of the Company

April 29, 2022 at 01:37 pm

BioVaxys Technology Corp. announce that Mr. Anthony Dutton has been appointed as a director of the Company.

Latest news about BioVaxys Technology Corp.

Biovaxys Technology Corp. Delays to File Its Interim Financial Statements for the Three Months Ended January 31, 2024	05-02	CI
BioVaxys Technology Corp. Appoints Christopher Cherry as Chief Financial Officer	04-30	CI
Biovaxys and SpayVac-For-Wildlife, Inc. Announce Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry	04-10	CI
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMage	04-03	CI
BioVaxys Technology Plans Private Placement; Down 5.9%	03-25	MT
BioVaxys Technology Corp. announced that it expects to receive CAD 1 million in funding	03-21	CI
Down 17%, BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	03-07	MT
BioVaxys Technology Corp. Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications	03-05	CI
Biovaxys Completes The Acquisition Of All Intellectual Property And Clinical Stage Assets Of The Former IMV Inc.	02-21	MT
BioVaxys Acquires Entire Technology Portfolio Of The Former IMV Inc.	02-12	MT
BioVaxys Technology Corp. announced that it has received CAD 1.605 million in funding	02-08	CI
BioVaxys Technology Corp. announced that it expects to receive CAD 1.6 million in funding	01-07	CI
BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Buy; Comes After BioVaxys and Procare Health Agreed to Terminate USA Distribution Agreement for Papilocare	12-22	MT
BioVaxys and Procare Health Agreed to Terminate USA Distribution Agreement for Papilocare	12-22	MT
BioVaxys Technology Corp. and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare and Immunocaps	12-20	CI
BioVaxys in Non-Binding Discussions for Major Immunotherapeutics Technology Acquisition	12-13	MT
BioVaxys Technology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	11-14	CI
BioVaxys Technology Corp. and The Ohio State University Extend Research Collaboration	28/08/23	CI
BioVaxys Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	29/06/23	CI
10402588 BC Ltd acquired TAETSoftware Corp.	12/06/23	CI
Biovaxys Technology Corp. Announces Chief Financial Officer Changes	07/06/23	CI
Biovaxys Technology Corp. Announces Corporate Secretary Changes	07/06/23	CI
Biovaxys Technology Corp. Announces Management Changes	12/04/23	CI
BioVaxys Technology Corp. Announces CFO Changes	12/04/23	CI
BioVaxys Technology Corp. Reports Earnings Results for the First Quarter Ended January 31, 2023	29/03/23	CI

Chart BioVaxys Technology Corp.

Duration

Period

More charts

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

Sector

Biotechnology & Medical Research

Calendar

26/06/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOVAXYS TECHNOLOGY CORP.	+40.00%	11.28M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B